LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN): Fresh Growth Sparks New Valuation Debate
AstraZeneca (LSE:AZN) has delivered double-digit growth in both revenue and net income over the past year. This performance has sparked renewed discussion about its potential for long-term returns. The company’s shares have gained 12% in the past month.
See our latest analysis for AstraZeneca.
AstraZeneca’s share price momentum has accelerated, with an 11.8% one-month gain and 16% return over the past quarter. Recent growth and a steady stream of scientific updates seem to have rekindled...